These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 22932786)

  • 1. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
    Tufano RP; Teixeira GV; Bishop J; Carson KA; Xing M
    Medicine (Baltimore); 2012 Sep; 91(5):274-286. PubMed ID: 22932786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk and Prognostic Factors for BRAF
    Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
    Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Surgery; 2015 Dec; 158(6):1500-11. PubMed ID: 26120069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
    Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
    JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Coexistent BRAF
    Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
    Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.
    Kim TH; Park YJ; Lim JA; Ahn HY; Lee EK; Lee YJ; Kim KW; Hahn SK; Youn YK; Kim KH; Cho BY; Park DJ
    Cancer; 2012 Apr; 118(7):1764-73. PubMed ID: 21882184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma.
    Zhang Q; Liu SZ; Zhang Q; Guan YX; Chen QJ; Zhu QY
    Cell Physiol Biochem; 2016; 38(2):763-76. PubMed ID: 26871894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
    Xing M; Westra WH; Tufano RP; Cohen Y; Rosenbaum E; Rhoden KJ; Carson KA; Vasko V; Larin A; Tallini G; Tolaney S; Holt EH; Hui P; Umbricht CB; Basaria S; Ewertz M; Tufaro AP; Califano JA; Ringel MD; Zeiger MA; Sidransky D; Ladenson PW
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6373-9. PubMed ID: 16174717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
    Xing M; Alzahrani AS; Carson KA; Viola D; Elisei R; Bendlova B; Yip L; Mian C; Vianello F; Tuttle RM; Robenshtok E; Fagin JA; Puxeddu E; Fugazzola L; Czarniecka A; Jarzab B; O'Neill CJ; Sywak MS; Lam AK; Riesco-Eizaguirre G; Santisteban P; Nakayama H; Tufano RP; Pai SI; Zeiger MA; Westra WH; Clark DP; Clifton-Bligh R; Sidransky D; Ladenson PW; Sykorova V
    JAMA; 2013 Apr; 309(14):1493-501. PubMed ID: 23571588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma.
    Lai HF; Hang JF; Kuo PC; Kuo CS; Yao SF; Chen JY; Lee CH
    Ann Surg Oncol; 2024 May; 31(5):3495-3501. PubMed ID: 38300401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.
    Li C; Lee KC; Schneider EB; Zeiger MA
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4559-70. PubMed ID: 23055546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Association between Lymphocytic Thyroiditis and Papillary Thyroid Cancer Harboring Mutant
    Perampalam S; Wu K; Gild M; Tacon L; Bullock M; Clifton-Bligh R
    Thyroid; 2024 Sep; 34(9):1082-1093. PubMed ID: 38940753
    [No Abstract]   [Full Text] [Related]  

  • 14. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
    Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
    World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity.
    Zoghlami A; Roussel F; Sabourin JC; Kuhn JM; Marie JP; Dehesdin D; Choussy O
    Eur Ann Otorhinolaryngol Head Neck Dis; 2014 Feb; 131(1):7-13. PubMed ID: 23845288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Association of BRAF(V) 600E mutation with clinical pathological features in papillary thyroid carcinoma: meta-analysis].
    Yan K; Lin X; Li S; Bao H; Zhao L; Liu X
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Sep; 49(9):759-64. PubMed ID: 25487587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome.
    Russo M; Malandrino P; Nicolosi ML; Manusia M; Marturano I; Trovato MA; Pellegriti G; Frasca F; Vigneri R
    Thyroid; 2014 Aug; 24(8):1267-74. PubMed ID: 24787545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis.
    Liu C; Chen T; Liu Z
    World J Surg Oncol; 2016 Sep; 14(1):241. PubMed ID: 27600854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
    Xing M
    Endocr Rev; 2007 Dec; 28(7):742-62. PubMed ID: 17940185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.